Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara A Byron

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Journal of the National Cancer Institute|September 10, 2025
Challenges in the return of molecular tumor profiling resultsHeinz-Josef Lenz, David W Craig, Kevin C Johnson, et al.
Gynecologic Oncology|March 19, 2017
FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group studyYvette W Jeske, Shamshad Ali, Sara A Byron, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|January 17, 2015
An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicineSara Nasser, Ahmet A Kurdolgu, Tyler Izatt, et al.
Journal for Immunotherapy of Cancer|May 5, 2026
Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinomaAmeish Govindarajan, Nathaniel Hansen, Benjamin D Mercier, et al.
Neuro-Oncology Advances|August 4, 2020
Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progressionMylan R Blomquist, Shannon Fortin Ensign, Fulvio D'Angelo, et al.
Molecular Cancer Research : MCR|January 17, 2009
Loss-of-function fibroblast growth factor receptor-2 mutations in melanomaMichael G Gartside, Huaibin Chen, Omar A Ibrahimi, et al.
Science Translational Medicine|January 11, 2023
Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancerKaran K Budhraja, Bradon R McDonald, Michelle D Stephens, et al.
Cancer Reports (Hoboken, N.J.)|March 31, 2022
A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastomaJacqueline M Kraveka, Elizabeth C Lewis, Genevieve Bergendahl, et al.
Investigational New Drugs|September 29, 2018
E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastasesHani M Babiker, Sara A Byron, William P D Hendricks, et al.
Neuro-Oncology|May 3, 2015
Toward precision medicine in glioblastoma: the promise and the challengesMichael D Prados, Sara A Byron, Nhan L Tran, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Journal of the National Cancer Institute|September 10, 2025
Challenges in the return of molecular tumor profiling resultsHeinz-Josef Lenz, David W Craig, Kevin C Johnson, et al.
Gynecologic Oncology|March 19, 2017
FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group studyYvette W Jeske, Shamshad Ali, Sara A Byron, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|January 17, 2015
An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicineSara Nasser, Ahmet A Kurdolgu, Tyler Izatt, et al.
Journal for Immunotherapy of Cancer|May 5, 2026
Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinomaAmeish Govindarajan, Nathaniel Hansen, Benjamin D Mercier, et al.
Neuro-Oncology Advances|August 4, 2020
Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progressionMylan R Blomquist, Shannon Fortin Ensign, Fulvio D'Angelo, et al.
Molecular Cancer Research : MCR|January 17, 2009
Loss-of-function fibroblast growth factor receptor-2 mutations in melanomaMichael G Gartside, Huaibin Chen, Omar A Ibrahimi, et al.
Science Translational Medicine|January 11, 2023
Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancerKaran K Budhraja, Bradon R McDonald, Michelle D Stephens, et al.
Cancer Reports (Hoboken, N.J.)|March 31, 2022
A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastomaJacqueline M Kraveka, Elizabeth C Lewis, Genevieve Bergendahl, et al.
Investigational New Drugs|September 29, 2018
E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastasesHani M Babiker, Sara A Byron, William P D Hendricks, et al.
Neuro-Oncology|May 3, 2015
Toward precision medicine in glioblastoma: the promise and the challengesMichael D Prados, Sara A Byron, Nhan L Tran, et al.
Pageof 4